engleski

Alloimmunization following allogenic heamtopoietis stem cell transplantation

In patients treated with allogeneic HSCT, there is a risk ofdeveloping new alloimmunization, due to exposure of donor lymphocytes to RBC ofthe recipient, or transfusion therapy with antigen incompatible blood components.After allogeneic HSCT, our patients developed alloantibodies of the Rhesus, Kell, MNS and Lutheran blood group systems that can cause significant hemolysis andcomplicate the course of recovery. Since some patients develop alloantibodiesdespite intensive immunosuppressive treatment, continuous immunohematologicalmonitoring is required for patients following HSCT.

alloimmunization, allogenic heamtopoietis, stem cell transplantation

nije evidentirano